Claims for Patent: 10,639,310

Summary for Patent: 10,639,310

Title:	Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
Abstract:	The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Inventor(s):	James D. Rodgers, Stacey Shepard
Assignee:	Incyte Corp , Incyte Holdings Corp
Application Number:	US16/177,602
Patent Claims:	1. A method of treating atopic dermatitis in a patient in need thereof, comprising administering to the skin of said patient a therapeutically effective amount of a compound, which is 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, wherein the treating refers to ameliorating or inhibiting atopic dermatitis in the patient. 2. The method of claim 1, wherein said compound or salt is administered in the form of a pharmaceutical composition suitable for skin administration, comprising said compound or salt and a pharmaceutically acceptable carrier. 3. A method of treating atopic dermatitis in a patient in need thereof, comprising administering to the skin of said patient a therapeutically effective amount of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, wherein the treating refers to ameliorating or inhibiting atopic dermatitis in the patient. 4. The method of claim 3, wherein said compound or salt is administered in the form of a pharmaceutical composition suitable for skin administration, comprising said compound or salt and a pharmaceutically acceptable carrier. 5. A method of treating atopic dermatitis in a patient in need thereof, comprising administering to the skin of said patient a therapeutically effective amount of a pharmaceutically acceptable salt of (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, wherein the treating refers to ameliorating or inhibiting atopic dermatitis in the patient. 6. The method of claim 5, wherein said salt is administered in the form of a pharmaceutical composition suitable for skin administration, comprising said salt and a pharmaceutically acceptable carrier.